Acceder
  1. Inicio
  2. Perfil de navise
  3. Participaciones

Participaciones del usuario navise

navise 25/09/12 18:02
Ha respondido al tema Farmas USA
Framus, a mi no me hagas mucho caso, que yo voy por intuiciones. En mi caso, he puesto stop en 1.35$
Ir a respuesta
navise 25/09/12 17:42
Ha respondido al tema Farmas USA
yo he vuelto a entrar, si veo en estos dias los 2.50$ me voy
Ir a respuesta
navise 25/09/12 14:16
Ha respondido al tema Chicharros USA - bolsa internacional
ha salido esta noticia,se ha dado al vuelta en el pre de -7 a 11% announced that the European Patent Office has granted a patent for the use of the ghrelin agonist, AEZS-130, related to methods and kits for use in relation to the diagnosis of growth hormone deficiency ("GHD") in a human or animal subject. Filed on February 19, 2007, the patent (EP #1984744 B1) titled, "Methods and Kits to Diagnose Growth Hormone Deficiency", was effective as of September 19, 2012, following its announcement in the European Patent Bulletin, and will expire on February 19, 2027. A similar patent has already Juergen Engel, Ph.D., Aeterna Zentaris President and CEO, commented, "This patent in Europe, along with the one already granted in the U.S., are key elements to ensure the protection of AEZS-130 for the diagnosis of GHD, in the world's two largest markets. We now look forward to filing a New Drug Application in the near future in the U.S. for AEZS-130, which could become the first approved oral diagnostic test for adults with GHD
Ir a respuesta
navise 25/09/12 14:15
Ha respondido al tema Farmas USA
dara me las quite el viernes, cachissss... notica de AEZS, en el pre estaba con -7% y ahora esta +11% en esta si estoy announced that the European Patent Office has granted a patent for the use of the ghrelin agonist, AEZS-130, related to methods and kits for use in relation to the diagnosis of growth hormone deficiency ("GHD") in a human or animal subject. Filed on February 19, 2007, the patent (EP #1984744 B1) titled, "Methods and Kits to Diagnose Growth Hormone Deficiency", was effective as of September 19, 2012, following its announcement in the European Patent Bulletin, and will expire on February 19, 2027. A similar patent has already Juergen Engel, Ph.D., Aeterna Zentaris President and CEO, commented, "This patent in Europe, along with the one already granted in the U.S., are key elements to ensure the protection of AEZS-130 for the diagnosis of GHD, in the world's two largest markets. We now look forward to filing a New Drug Application in the near future in the U.S. for AEZS-130, which could become the first approved oral diagnostic test for adults with GHD
Ir a respuesta
navise 24/09/12 22:36
Ha respondido al tema Chicharros USA - bolsa internacional
Noticia de Heb Hemispherx BioPharma, Inc(NYSEAMEX:HEB) shares jumped 9% to $1.09 after the company announced that the U.S. Food and Drug Administration has tentatively scheduled an Advisory Committee meeting to discuss the Ampligen(R) New Drug Application for Chronic Fatigue Syndrome which is currently under review by the FDA. The date of the AC review has been tentatively set for December 20, 2012. As previously announced, the Prescription Drug User Fee Act (“PDUFA”) review goal for the FDA to complete its review is February 2, 2013.
Ir a respuesta
navise 24/09/12 19:43
Ha respondido al tema Farmas USA
El jefe dijo que iva todo según lo previsto. Asi que a esperar toca Yo en mi caso, cuando llegue a 9 (si lo hace)suelto la mitad
Ir a respuesta